US EditionPublished • loading... • Updated
iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
Summary by icrowdnewswire.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients
Study Aims to Expedite Potentially Transformative Therapies By Assessing Safety and Efficacy of FSD202 Melbourne, Australia – June 02, 2025 – iNGENū CRO, a leading full-service Contract Research Organization (CRO) in the Asia-Pacific region, is proud to announce its operational leadership role in a Phase 2 clinical trial launched in partnership with Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91), a biopharmaceutical company dedica…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
